SK4198A3 - Use of 1,4-dihydropyridine derivatives in the prevention and therapy of atherosclerotic degradation of arterial walls - Google Patents

Use of 1,4-dihydropyridine derivatives in the prevention and therapy of atherosclerotic degradation of arterial walls Download PDF

Info

Publication number: SK4198A3
Authority: SK; Slovakia
Prior art keywords: lercanidipine; medicament; compound; preparation; use according
Prior art date: 1995-07-14

Application number

SK41-98A

Other languages

English (en)

Slovak (sk)

Inventor

Abraham Sartani

Amedeo Leonardi

Rodolfo Testa

Original Assignee

Recordati Chem Pharm

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-14

Filing date

1996-06-28

Publication date

1998-05-06

1996-06-28 Application filed by Recordati Chem Pharm filed Critical Recordati Chem Pharm

1998-05-06 Publication of SK4198A3 publication Critical patent/SK4198A3/sk

Links

230000003143 atherosclerotic effect Effects 0.000 title claims abstract description 15
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 title abstract description 15
230000015556 catabolic process Effects 0.000 title abstract description 3
238000006731 degradation reaction Methods 0.000 title abstract description 3
230000002265 prevention Effects 0.000 title description 3
238000002560 therapeutic procedure Methods 0.000 title 1
ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 claims abstract description 51
229960004294 lercanidipine Drugs 0.000 claims abstract description 50
239000003814 drug Substances 0.000 claims abstract description 20
ZDXUKAKRHYTAKV-XIFFEERXSA-N 5-o-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-o-methyl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-XIFFEERXSA-N 0.000 claims abstract description 7
ZDXUKAKRHYTAKV-MGBGTMOVSA-N 5-o-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-o-methyl (4r)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-MGBGTMOVSA-N 0.000 claims abstract description 4
150000001875 compounds Chemical class 0.000 claims description 29
-1 2-nitrophenyl Chemical group 0.000 claims description 18
238000002360 preparation method Methods 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 9
125000004432 carbon atom Chemical group C* 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 6
239000012453 solvate Substances 0.000 claims description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 51
108010007622 LDL Lipoproteins Proteins 0.000 abstract description 28
102000007330 LDL Lipoproteins Human genes 0.000 abstract description 28
210000000107 myocyte Anatomy 0.000 abstract description 23
238000000034 method Methods 0.000 abstract description 22
210000002540 macrophage Anatomy 0.000 abstract description 14
230000005012 migration Effects 0.000 abstract description 8
238000013508 migration Methods 0.000 abstract description 8
230000008569 process Effects 0.000 abstract description 7
230000035755 proliferation Effects 0.000 abstract description 7
238000011161 development Methods 0.000 abstract description 5
230000001590 oxidative effect Effects 0.000 abstract description 4
230000004060 metabolic process Effects 0.000 abstract description 3
231100000216 vascular lesion Toxicity 0.000 abstract description 3
238000004519 manufacturing process Methods 0.000 abstract description 2
238000012986 modification Methods 0.000 abstract 1
230000004048 modification Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 35
235000012000 cholesterol Nutrition 0.000 description 22
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 21
230000000694 effects Effects 0.000 description 20
230000003647 oxidation Effects 0.000 description 18
238000007254 oxidation reaction Methods 0.000 description 18
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
238000011534 incubation Methods 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
238000005886 esterification reaction Methods 0.000 description 12
239000002609 medium Substances 0.000 description 12
108091003079 Bovine Serum Albumin Proteins 0.000 description 11
150000001840 cholesterol esters Chemical class 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
230000032050 esterification Effects 0.000 description 10
239000000243 solution Substances 0.000 description 10
201000001320 Atherosclerosis Diseases 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
239000002253 acid Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
241000700159 Rattus Species 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
239000004480 active ingredient Substances 0.000 description 7
239000012267 brine Substances 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
206010020772 Hypertension Diseases 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
229940079593 drug Drugs 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
239000002904 solvent Substances 0.000 description 6
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
102000004895 Lipoproteins Human genes 0.000 description 5
108090001030 Lipoproteins Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
230000003276 anti-hypertensive effect Effects 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000012894 fetal calf serum Substances 0.000 description 5
230000003902 lesion Effects 0.000 description 5
XKORCTIIRYKLLG-ARJAWSKDSA-N methyl (z)-3-aminobut-2-enoate Chemical compound COC(=O)\C=C(\C)N XKORCTIIRYKLLG-ARJAWSKDSA-N 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
210000000329 smooth muscle myocyte Anatomy 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
JPXPPUOCSLMCHK-UHFFFAOYSA-N 5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid Chemical compound COC(=O)C1=C(C)NC(C)=C(C(O)=O)C1C1=CC=CC([N+]([O-])=O)=C1 JPXPPUOCSLMCHK-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
239000010949 copper Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
125000006501 nitrophenyl group Chemical group 0.000 description 4
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
210000003024 peritoneal macrophage Anatomy 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010003210 Arteriosclerosis Diseases 0.000 description 3
208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000004872 arterial blood pressure Effects 0.000 description 3
208000011775 arteriosclerosis disease Diseases 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
208000026106 cerebrovascular disease Diseases 0.000 description 3
230000003399 chemotactic effect Effects 0.000 description 3
239000005515 coenzyme Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
210000000497 foam cell Anatomy 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000012071 phase Substances 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
102000057234 Acyl transferases Human genes 0.000 description 2
108700016155 Acyl transferases Proteins 0.000 description 2
239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 2
239000006145 Eagle's minimal essential medium Substances 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000035150 Hypercholesterolemia Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000035508 accumulation Effects 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
150000001266 acyl halides Chemical class 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
244000309464 bull Species 0.000 description 2
244000309466 calf Species 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
230000008021 deposition Effects 0.000 description 2
150000001993 dienes Chemical class 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000002900 effect on cell Effects 0.000 description 2
238000000921 elemental analysis Methods 0.000 description 2
239000000686 essence Substances 0.000 description 2
238000010931 ester hydrolysis Methods 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
229960004340 lacidipine Drugs 0.000 description 2
GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 2
230000006372 lipid accumulation Effects 0.000 description 2
230000003859 lipid peroxidation Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
239000007758 minimum essential medium Substances 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
208000031225 myocardial ischemia Diseases 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
108010071584 oxidized low density lipoprotein Proteins 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
210000002254 renal artery Anatomy 0.000 description 2
206010038464 renal hypertension Diseases 0.000 description 2
102000014452 scavenger receptors Human genes 0.000 description 2
108010078070 scavenger receptors Proteins 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
238000003756 stirring Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
238000005199 ultracentrifugation Methods 0.000 description 2
230000002792 vascular Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
ZQPPMHVWECSIRJ-JVBZJRCZSA-N (z)-octadec-9-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCC[14C](O)=O ZQPPMHVWECSIRJ-JVBZJRCZSA-N 0.000 description 1
UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
XHTYQFMRBQUCPX-UHFFFAOYSA-N 1,1,3,3-tetramethoxypropane Chemical compound COC(OC)CC(OC)OC XHTYQFMRBQUCPX-UHFFFAOYSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
MQWDISMNBYOLAB-UHFFFAOYSA-N 1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-ol Chemical compound C=1C=CC=CC=1C(CCN(C)CC(C)(C)O)C1=CC=CC=C1 MQWDISMNBYOLAB-UHFFFAOYSA-N 0.000 description 1
GUXKBDHITFXEJG-UHFFFAOYSA-N 5-methoxycarbonylpyridine-3-carboxylic acid Chemical compound COC(=O)C1=CN=CC(C(O)=O)=C1 GUXKBDHITFXEJG-UHFFFAOYSA-N 0.000 description 1
229940123324 Acyltransferase inhibitor Drugs 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
102000000853 LDL receptors Human genes 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
229920003106 Methocel™ A4C Polymers 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000007997 Tricine buffer Substances 0.000 description 1
206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000002404 acyltransferase inhibitor Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
208000007474 aortic aneurysm Diseases 0.000 description 1
210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000012911 assay medium Substances 0.000 description 1
230000036523 atherogenesis Effects 0.000 description 1
CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
238000003516 cell number determination Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
230000001637 coronarodilatory effect Effects 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
210000004177 elastic tissue Anatomy 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
235000004626 essential fatty acids Nutrition 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000002695 general anesthesia Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
230000005484 gravity Effects 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
108010022197 lipoprotein cholesterol Proteins 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940118019 malondialdehyde Drugs 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
229940012189 methyl orange Drugs 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229960001783 nicardipine Drugs 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
108700038606 rat Smooth muscle Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
238000005185 salting out Methods 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
230000015590 smooth muscle cell migration Effects 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
YZYDOFGGDSDUPX-UHFFFAOYSA-M sodium;carbonic acid;chloride Chemical compound [Na+].[Cl-].OC(O)=O YZYDOFGGDSDUPX-UHFFFAOYSA-M 0.000 description 1
FVAUCKIRQBBSSJ-FXMLPJBTSA-M sodium;iodine-125(1-) Chemical compound [Na+].[125I-] FVAUCKIRQBBSSJ-FXMLPJBTSA-M 0.000 description 1
241000894007 species Species 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
230000008719 thickening Effects 0.000 description 1
229940071127 thioglycolate Drugs 0.000 description 1
CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
230000035899 viability Effects 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
General Chemical & Material Sciences (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)

SK41-98A 1995-07-14 1996-06-28 Use of 1,4-dihydropyridine derivatives in the prevention and therapy of atherosclerotic degradation of arterial walls SK4198A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ITMI951513A IT1275532B (it)	1995-07-14	1995-07-14	Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
PCT/EP1996/002872 WO1997003669A1 (en)	1995-07-14	1996-06-28	Use of 1,4-dihydropyridine derivatives in the prevention and therapy of atherosclerotic degradation of arterial walls

Publications (1)

Publication Number	Publication Date
SK4198A3 true SK4198A3 (en)	1998-05-06

Family

ID=11371972

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK41-98A SK4198A3 (en)	1995-07-14	1996-06-28	Use of 1,4-dihydropyridine derivatives in the prevention and therapy of atherosclerotic degradation of arterial walls

Country Status (19)

Country	Link
EP (1)	EP0839036B1 (de)
JP (1)	JPH11509214A (de)
KR (1)	KR19990028741A (de)
CN (1)	CN1190345A (de)
AT (1)	ATE183644T1 (de)
AU (1)	AU690471B2 (de)
CA (1)	CA2219501A1 (de)
CZ (1)	CZ11698A3 (de)
DE (1)	DE69603968T2 (de)
DK (1)	DK0839036T3 (de)
ES (1)	ES2138359T3 (de)
GR (1)	GR3031096T3 (de)
HU (1)	HUP9802736A3 (de)
IL (1)	IL122302A (de)
IT (1)	IT1275532B (de)
NO (1)	NO980171D0 (de)
SK (1)	SK4198A3 (de)
WO (1)	WO1997003669A1 (de)
ZA (1)	ZA965924B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6852737B2 (en)	2001-08-06	2005-02-08	Recordati Ireland Limited	Crude and crystalline forms of lercanidipine hydrochloride
ITMI20011726A1 (it) *	2001-08-06	2003-02-06	Recordati Ind Chimica E Farma	Forme polimorfe della lercanidipina cloridrato
TW200613275A (en) *	2004-08-24	2006-05-01	Recordati Ireland Ltd	Lercanidipine salts
AR053023A1 (es) *	2005-02-25	2007-04-18	Recordati Ireland Ltd	Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
EA027787B1 (ru)	2010-06-23	2017-09-29	Крка, Товарна Здравил, Д.Д., Ново Место	Пероральные лекарственные формы, содержащие лерканидипин и эналаприл и их фармацевтически приемлемые соли
PL2627173T5 (pl)	2010-10-12	2019-11-29	Chiesi Farm Spa	Formulacje emulsyjne klewidypiny zawierające środki przeciw mikrobom
US8658676B2 (en)	2010-10-12	2014-02-25	The Medicines Company	Clevidipine emulsion formulations containing antimicrobial agents
WO2012085249A2 (en)	2010-12-24	2012-06-28	Krka, D.D., Novo Mesto	Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8403866D0 (en) *	1984-02-14	1984-03-21	Recordati Chem Pharm	Diphenylalkylaminoalkyl esters

1995
- 1995-07-14 IT ITMI951513A patent/IT1275532B/it active IP Right Grant
1996
- 1996-06-28 EP EP96924834A patent/EP0839036B1/de not_active Expired - Lifetime
- 1996-06-28 AU AU65164/96A patent/AU690471B2/en not_active Ceased
- 1996-06-28 HU HU9802736A patent/HUP9802736A3/hu unknown
- 1996-06-28 KR KR1019980700039A patent/KR19990028741A/ko not_active Withdrawn
- 1996-06-28 CA CA002219501A patent/CA2219501A1/en not_active Abandoned
- 1996-06-28 CZ CZ98116A patent/CZ11698A3/cs unknown
- 1996-06-28 IL IL12230296A patent/IL122302A/xx not_active IP Right Cessation
- 1996-06-28 CN CN96195439A patent/CN1190345A/zh active Pending
- 1996-06-28 DK DK96924834T patent/DK0839036T3/da active
- 1996-06-28 WO PCT/EP1996/002872 patent/WO1997003669A1/en not_active Ceased
- 1996-06-28 SK SK41-98A patent/SK4198A3/sk unknown
- 1996-06-28 ES ES96924834T patent/ES2138359T3/es not_active Expired - Lifetime
- 1996-06-28 DE DE69603968T patent/DE69603968T2/de not_active Expired - Fee Related
- 1996-06-28 JP JP9506222A patent/JPH11509214A/ja active Pending
- 1996-06-28 AT AT96924834T patent/ATE183644T1/de not_active IP Right Cessation
- 1996-07-12 ZA ZA965924A patent/ZA965924B/xx unknown
1998
- 1998-01-14 NO NO980171A patent/NO980171D0/no not_active Application Discontinuation
1999
- 1999-08-26 GR GR990402179T patent/GR3031096T3/el unknown

Also Published As

Publication number	Publication date
HUP9802736A3 (en)	2000-03-28
DE69603968T2 (de)	2000-04-06
EP0839036B1 (de)	1999-08-25
CA2219501A1 (en)	1997-02-06
ES2138359T3 (es)	2000-01-01
CN1190345A (zh)	1998-08-12
ZA965924B (en)	1997-01-30
HUP9802736A2 (hu)	1999-03-29
KR19990028741A (ko)	1999-04-15
WO1997003669A1 (en)	1997-02-06
DE69603968D1 (de)	1999-09-30
GR3031096T3 (en)	1999-12-31
IL122302A0 (en)	1998-04-05
CZ11698A3 (cs)	1998-06-17
IL122302A (en)	2000-08-13
ATE183644T1 (de)	1999-09-15
NO980171L (no)	1998-01-14
IT1275532B (it)	1997-08-07
JPH11509214A (ja)	1999-08-17
ITMI951513A1 (it)	1997-01-14
DK0839036T3 (da)	2000-01-24
NO980171D0 (no)	1998-01-14
EP0839036A1 (de)	1998-05-06
AU6516496A (en)	1997-02-18
ITMI951513A0 (it)	1995-07-14
AU690471B2 (en)	1998-04-23

Publication	Publication Date	Title
US5912351A (en)	1999-06-15	Anhydrous 1,4-Dihydropyridines and salts thereof
SK4198A3 (en)	1998-05-06	Use of 1,4-dihydropyridine derivatives in the prevention and therapy of atherosclerotic degradation of arterial walls
US5696139A (en)	1997-12-09	Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
JPH03503525A (ja)	1991-08-08	腫瘍疾患治療用の光学的に純粋なｒ‐（‐）‐ニグルジピン及びその誘導体
WO1997009301A1 (en)	1997-03-13	2-acylaminobenzamide derivatives and preventive and remedy for diseases caused by the supermultiplication of vascular intimal cells
US5691339A (en)	1997-11-25	Circulatory disorder improving agent
US5530001A (en)	1996-06-25	Pharmaceutical use of dihydropyridine derivative
MXPA98000387A (en)	1999-06-01	Use of 1,4-dihydropyridine derivatives in the prevention and atterosclerotic degradation therapy of artery walls
JP4783152B2 (ja)	2011-09-28	血管内膜肥厚抑制薬
JPH0529209B2 (de)	1993-04-28
EP1206936B1 (de)	2005-08-24	Phenylessigsäure-Zusammensetzungen zur Behandlung oder Vorbeugung von Hypercholesterolemia
US20120022088A1 (en)	2012-01-26	Pharmaceutical combination of 5-fluorouracil and derivate of 1,4-dihydropyridine and its use in the treatment of cancer
NZ204283A (en)	1985-11-08	Dihydropyridine derivatives and pharmaceutical compositions
JPH02243679A (ja)	1990-09-27	腫瘍転移阻害剤
JPH09501923A (ja)	1997-02-25	薬剤としてのｎ−アルキル化された１，４−ジヒドロピリジンジカルボン酸エステル類の使用
CN119591564A (zh)	2025-03-11	伏硫西汀长效前药衍生物、其药物组合物及用途
KR20050039700A (ko)	2005-04-29	이식거부 치료용 화합물 및 치료 방법
KR20060125816A (ko)	2006-12-06	호중구증다 억제제
WO1996035420A1 (en)	1996-11-14	Use of(s)-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
JPH08165239A (ja)	1996-06-25	抗動脈硬化剤
JPS6187679A (ja)	1986-05-06	化合物および医薬組成物
HK1048588B (en)	2006-01-13	Phenylacetic acid compositions for treating or preventing hypercholesterolemia
JPH08291127A (ja)	1996-11-05	ヒドロキサム酸誘導体およびそれを含有する医薬製剤
JPWO1997025986A1 (ja)	1998-05-26	血管内膜肥厚抑制剤
JPWO1998046573A1 (ja)	2000-10-03	２−置換カルバモイルイミダゾールカルボン酸誘導体および血管壁肥厚抑制剤